News >

FDA Approves Luspatercept for Beta Thalassemia–Associated Anemia

Gina Columbus @ginacolumbusonc
Published: Friday, Nov 08, 2019

The FDA has approved luspatercept-aamt (Reblozyl) for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication